Overexpression of p21, cyclin E and decreased expression of p27 in DMBA (7, 12-dimethylbenzanthracene)-induced rat ovarian carcinogenesis

Pathology International

Volumn 53, Issue 5, 2003, Pages 291-296

  Kim, Ki Kwon ^a   Shim, Jae Chul ^a   Kim, Jung Ran ^a  

^a Dongguk University College of Medicine   (South Korea)

Author keywords

Cyclin E; Ovarian cancer; p21; p27; Rat

Indexed keywords

CYCLIN E; DIMETHYLBENZ[A]ANTHRACENE; PROTEIN P21; PROTEIN P27;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; EPITHELIUM; EVALUATION; FEMALE; IMMUNOHISTOCHEMISTRY; NONHUMAN; OVARY CANCER; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; WESTERN BLOTTING;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ADENOCARCINOMA; ANIMALS; CARCINOGENS; CYCLIN E; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; FEMALE; MICROFILAMENT PROTEINS; MUSCLE PROTEINS; OVARIAN NEOPLASMS; RATS; RATS, SPRAGUE-DAWLEY; TUMOR MARKERS, BIOLOGICAL;

EID: 0038792394     PISSN: 13205463     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1827.2003.01477.x     Document Type: Article

References (31)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999; 49: 8-31.
2. DelSal G, Loda M, Pagano M. Cell cycle and cancer: critical events at the G1 restriction point. Crit Rev Oncogen 1996; 7: 127-42.
3. Sherr CJ. Cancer cell cycle. Science 1996; 274: 1672-7.
4. Nielsen NH, Arnerlov C, Emdin SO, Landberg G. Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status. Br J Cancer 1996; 74: 874-80.
5. Sakaguchi T, Watanabe A, Sawada H et al. Prognostic value of cyclin E and p53 expression in gastric carcinoma. Cancer 1998; 82: 1238-43.
6. Wang A, Yoshimi N, Suzul M, Yamauchi A, Tarao M, Mori H. Different expression patterns of cyclins A, D1 and E in human colorectal cancer. J Cancer Res Clin Oncol 1996; 122: 122-6.
7. Ohtsubo M, Theodoras AM, Schumacher J, Roberts JM, Pagano M. Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol Cell Biol 1995; 15: 2612-24.
8. Kitahara K, Yasui W, Kuniyasu H et al. Concurrent amplification of cyclin E and CDK2 genes in colorectal carcinomas. Int J Cancer 1995; 62: 25-8.
9. El-Deiry WS, Tokino T, Velculescu VE et al. WAF1, a potent mediator of p53 tumor suppression. Cell 1993; 75: 817-25.
10. El-Deiry WS, Tokino T, Waldman T et al. Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res 1995; 55: 2910-19.
11. Polyak K, Lee MH, Erdjument-Bromage H et al. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994; 78: 59-66.
12. Katayose Y, Kim M, Rakkar AN, Li Z, Cowan KH, Seth P. Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27. Cancer Res 1997; 57: 5441-5.
13. Sekiya S, Endoh N, Kikuchi Y et al. In vivo and in vitro studies of experimental ovarian adenocarcinoma in rats. Cancer Res 1979; 39: 1108-12.
14. Nishida T, Sugiyama T, Katabuchi H, Kamura N, Yakushiji M, Kato T. Histologic origin of rat ovarian adenocarcinoma induced by direct application of 7, 12-dimethylbenz[a]anthracene. Acta Obstet Gynecol Jpn 1986; 38: 570-74.
15. Nishida T, Sugiyama T, Kataoka A, Ushijima K, Yakushiji M. Histologic characterization of rat ovarian carcinoma induced by intraovarian insertion of a 7, 12-dimethylbenz[a]anthracene-coated suture. Cancer 1998; 83: 965-70.
16. Masciullo V, Sgambato A, Pacilio C et al. Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer. Cancer Res 1999; 59: 3790-94.
17. Sui L, Dong Y, Ohno M et al. Implication of malignancy and prognosis of p27 (kip1), Cyclin E, and CDK2 expression in epithelial ovarian tumors. Gynecol Oncol 2001; 83: 56-63.
18. Pagano M, Tam SW, Theodoras AM et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995; 269: 682-5.
19. Loda M, Cukor B, Tam S et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997; 3: 231-4.
20. Ciaparrone M, Yamamoto H, Yao Y et al. Localization and expression of p27kip1 in multistage colorectal carcinogenesis. Cancer Res 1998; 58: 114-22.
21. Guo Y, Sklar GN, Borkowski A, Kyprianou N. Loss of the cyclin-dependent kinase inhibitor p27 protein in human prostate cancer correlates with tumor grade. Clin Cancer Res 1997; 3: 2269-74.
22. Singh SP, Lipman J, Goldman H et al. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res 1998; 58: 1730-35.
23. Soucek T, Yeung RS, Hengstschlager M. Inactivation of the cyclin-dependent kinase inhibitor p27 upon loss of the tuberous sclerosis complex gene-2. Proc Natl Acad Sci USA 1998; 95: 15 653-8.
24. Tomoda K, Kubota Y, Kato J. Degradation of the cyclin-dependent-kinase inhibitor p27 kip1 is instigated by Jab1. Nature (Lond) 1999; 398: 160-65.
25. Courjal F, Louason G, Speiser P, Katsaros D, Zeillinger R, Theillet C. Cyclin gene amplification and overexpression in breast and ovarian cancers: evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors. Int J Cancer 1996; 69: 247-53.
26. Sewing A, Ronicke V, Burger C, Funk M, Muller R. Alternative splicing of human cyclin E. J Cell Sci 1994; 107: 581-8.
27. Barboule N, Mazars P, Baldin V et al. Expression of p21WAF1/CIP1 is heterogeneous and unrelated to proliferation index in human ovarian carcinoma. Int J Cancer 1995; 63: 611-15.
28. Jung JM, Bruner JM, Ruan S et al. Increased levels of p21WAF1/Cip1 in human brain tumors. Oncogene 1995; 11: 2021-8.
29. Marchetti A, Dogliono C, Barbareschi M et al. p21 RNA and protein expression in non-small-cell lung carcinomas: evidence of p53-independent expression and association with tumoral differentiation. Oncogene 1996; 12: 1319-24.
30. Moll UM, Laquaglia M, Benard J, Riou G. Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc Natl Acad Sci USA 1995; 92: 4407-41.
31. El-Deiry WS, Harper JW, O'Connor PM et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994; 54: 1169-74.